Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–9. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997;40(1):15–24. doi:10.1007/BF02055676.
   PubMed Web of Science ®Google Scholar
• Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–877. doi:10.1200/JCO.2008.19.5362.
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827–830. doi:10.1126/science.1195300.
   PubMed Web of Science ®Google Scholar
• Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48(7):353–362. doi:10.1007/s002620050586.
   PubMed Web of Science ®Google Scholar
• Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19(11):1821–1828. doi:10.1093/annonc/mdn386.
   PubMed Web of Science ®Google Scholar
• Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12(2):133–143. doi:10.1038/nrc3184.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Clarke MF. Clinical and Therapeutic Implications of Cancer Stem Cells. N Engl J Med. 2019;380(23):2237–2245. doi:10.1056/NEJMra1804280.
   PubMed Web of Science ®Google Scholar
• Zhang D, Tang DG, Rycaj K. Cancer stem cells: regulation programs, immunological properties and immunotherapy. Semin Cancer Biol. 2018;52:94–106. doi:10.1016/j.semcancer.2018.05.001.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Kochin V, Kanaseki T, Hongo A, Tokita S, Kikuchi Y, Takaya A, Hirohashi Y, Tsukahara T, Terui T, et al. The antigen ASB4 on cancer stem cells serves as a target for CTL immunotherapy of colorectal cancer. Cancer Immunol Res. 2018;6(3):358–369. doi:10.1158/2326-6066.CIR-17-0518.
   PubMed Web of Science ®Google Scholar
• Fan J, Shang D, Han B, Song J, Chen H, Yang JM. Adoptive cell transfer: is it a promising immunotherapy for colorectal cancer? Theranostics. 2018;8(20):5784–5800. doi:10.7150/thno.29035.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139–149. doi:10.1084/jem.174.1.139.
   PubMed Web of Science ®Google Scholar
• Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015;141(5):839–849. doi:10.1007/s00432-014-1864-3.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen CL, Jiang SW, Feng Y, Yuan L, Chen P, Zhang L, Huang S, Li J, Xia J-C, et al. Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncoimmunology. 2019;8(2):e1528411. doi:10.1080/2162402X.2018.1528411.
   PubMed Web of Science ®Google Scholar
• Pan QZ, Tang Y, Wang QJ, Li YQ, Zhang L, Li XD, Zhao -J-J, Weng D-S, Liu Q, Huang L-X, et al. Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology. 2015;4(9):e1038017. doi:10.1080/2162402X.2015.1038017.
   PubMed Web of Science ®Google Scholar
• Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao -J-J, Qiu H-J, Weng D-S, Li -J-J, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20(13):4305–4311. doi:10.1245/s10434-013-3144-x.
   PubMed Web of Science ®Google Scholar
• Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, Weng D-S, Wang Q-J, Liu Q, Huang L-X, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res. 2014;20(11):3003–3011. doi:10.1158/1078-0432.CCR-14-0082.
   PubMed Web of Science ®Google Scholar
• Li JJ, Gu MF, Pan K, Liu LZ, Zhang H, Shen WX, Xia J-C. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012;35(2):189–195. doi:10.1097/CJI.0b013e318241d9de.
   PubMed Web of Science ®Google Scholar
• Zhou X, Mo X, Qiu J, Zhao J, Wang S, Zhou C, Su Y, Lin Z, Ma H. Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:5363–5372. doi:10.2147/CMAR.S173201.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng Z, Zhang Q, Zhou X, Feng Y, Yan A. FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis. Onco Targets Ther. 2017;10:2621–2633. doi:10.2147/OTT.S138011.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang H, Li Y, Bai J, Liu L, Liu Y, Qu Y, Qu X. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother. 2013;62(10):1629–1635. doi:10.1007/s00262-013-1465-z.
   PubMed Web of Science ®Google Scholar
• Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018;19(4):562–578. doi:10.1016/S1470-2045(18)30093-7.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177–1188. doi:10.1056/NEJMoa1713709.
   PubMed Web of Science ®Google Scholar
• Mata-Molanes JJ, Sureda Gonzalez M, Valenzuela Jimenez B, Martinez Navarro EM, Brugarolas Masllorens A. Cancer immunotherapy with cytokine-induced killer cells. Target Oncol. 2017;12(3):289–299. doi:10.1007/s11523-017-0489-2.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang Y, Yu J, Wei F, Cao S, Zhang X, Dong N, Li H, Ren X. Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. Clin Colorectal Cancer. 2016;15(3):228–235. doi:10.1016/j.clcc.2016.02.005.
   PubMed Web of Science ®Google Scholar
• Xie Y, Huang L, Chen L, Lin X, Chen L, Zheng Q. Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. World J Surg Oncol. 2017;15(1):209. doi:10.1186/s12957-017-1278-1.
   PubMedGoogle Scholar
• Zhang J, Zhu L, Zhang Q, He X, Yin Y, Gu Y, Guo R, Lu K, Liu L, Liu P, et al. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study. Biomed Pharmacother. 2014;68(6):715–720. doi:10.1016/j.biopha.2014.07.010.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim YG, Park EJ, Kim B, Lee HK, Hong JT, Kim Y, Han S-B. Cell-based immunotherapy for colorectal cancer with cytokine-induced killer cells. Immune Netw. 2016;16(2):99–108. doi:10.4110/in.2016.16.2.99.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103(8):3065–3072. doi:10.1182/blood-2003-06-2125.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol. 1996;169(1):85–90. doi:10.1006/cimm.1996.0094.
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, et al. Cytokine-induced killer cells kill chemo-surviving melanoma cancer stem cells. Clin Cancer Res. 2017;23(9):2277–2288. doi:10.1158/1078-0432.CCR-16-1524.
   PubMed Web of Science ®Google Scholar
• Lin T, Song C, Chuo DY, Zhang H, Zhao J. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumour Biol. 2016;37(4):4367–4372. doi:10.1007/s13277-015-3957-2.
   PubMedGoogle Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673–1679.
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–1696.
   PubMed Web of Science ®Google Scholar
• Snaebjornsson P, Coupe VM, Jonasson L, Meijer GA, van Grieken NC, Jonasson JG. pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd’s local peritoneal involvement revisited. Int J Cancer. 2014;135(2):467–478. doi:10.1002/ijc.28676.
   PubMed Web of Science ®Google Scholar
• Andre T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. J Clin Oncol. 2018;36(15):1469–1477. doi:10.1200/JCO.2017.76.0355.
   PubMed Web of Science ®Google Scholar
• Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(16):1436–1447. doi:10.1200/JCO.19.00281.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121(4):527–534. doi:10.1002/cncr.29072.
   PubMed Web of Science ®Google Scholar
• Qiao G, Wang X, Zhou L, Zhou X, Song Y, Wang S, Zhao L, Morse MA, Hobeika A, Song J, et al. Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: a prospective study. Clin Cancer Res. 2019;25(5):1494–1504. doi:10.1158/1078-0432.CCR-18-2360.
   PubMed Web of Science ®Google Scholar